Crawford Dennis C, Heveran Chelsea M, Cannon W Dilworth, Foo Li Foong, Potter Hollis G
Department of Orthopaedics, Oregon Health and Science University, Portland, Oregon 97239, USA.
Am J Sports Med. 2009 Jul;37(7):1334-43. doi: 10.1177/0363546509333011. Epub 2009 May 15.
The healing potential of damaged articular cartilage is limited. The NeoCart is a tissue-engineered collagen matrix seeded with autogenous chondrocytes designed for the repair of hyaline articular cartilage.
The NeoCart implant is well tolerated in the human knee.
Case series; Level of evidence, 4.
Eight patients (treatment group) with full-thickness cartilage injury were treated with the NeoCart and evaluated prospectively. Autogenous chondrocytes provided by arthroscopic biopsy were seeded into a 3-dimensional type I collagen scaffold. The seeded scaffold was subjected to a tissue-engineering protocol including treatment with a bioreactor. Implantation of the prepared cartilage tissue patch was performed via miniarthrotomy and secured with a collagen bioadhesive. Evaluations through 24 months postoperatively included the subjective International Knee Documentation Committee questionnaire, visual analog scale, range of motion, and cartilage-sensitive magnetic resonance imaging (MRI), including quantitative T2 mapping.
Pain scores after NeoCart implantation were significantly lower than baseline at 12 and 24 months after the procedure (P < .05). Improved function and motion were also noted at 24 months. Six patients had 67% to 100% defect fill at 24 months with MRI evaluation. One patient had moderate (33%-66%) defect fill, and another patient had poor (less than 33%) defect fill. Partial stratification of T2 values was observed for 2 patients at 12 months and 4 patients at 24 months. No patients experienced arthrofibrosis or implant hypertrophy.
Pain was significantly reduced 12 and 24 months after NeoCart treatment. Trends toward improved function and motion were observed 24 months after implantation. The MRI indicated implant stability and peripheral integration, defect fill without overgrowth, progressive maturation, and more organized cartilage formation.
受损关节软骨的愈合潜力有限。NeoCart是一种组织工程化胶原基质,接种有自体软骨细胞,用于修复透明关节软骨。
NeoCart植入物在人体膝关节中耐受性良好。
病例系列;证据等级,4级。
8例全层软骨损伤患者(治疗组)接受NeoCart治疗并进行前瞻性评估。通过关节镜活检获取的自体软骨细胞接种到三维I型胶原支架中。接种后的支架经过组织工程流程,包括生物反应器处理。通过小切口手术植入制备好的软骨组织补片,并用胶原生物黏合剂固定。术后24个月的评估包括国际膝关节文献委员会主观问卷、视觉模拟评分、活动范围以及软骨敏感磁共振成像(MRI),包括定量T2成像。
NeoCart植入术后12个月和24个月时,疼痛评分显著低于基线水平(P < .05)。术后24个月时还观察到功能和活动改善。6例患者在术后24个月的MRI评估中缺损填充率为67%至100%。1例患者缺损填充率为中等(33% - 66%),另1例患者缺损填充率较差(低于33%)。2例患者在术后12个月、4例患者在术后24个月观察到T2值部分分层。没有患者出现关节纤维化或植入物肥大。
NeoCart治疗后12个月和24个月时疼痛显著减轻。植入术后24个月观察到功能和活动有改善趋势。MRI显示植入物稳定且与周围整合良好,缺损填充但无过度生长,逐渐成熟,软骨形成更有序。